News-arkiv - Isofol Medical

Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin

GOTHENBURG, Sweden, July 8, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed […]

GOTHENBURG, Sweden, May 19, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the “Company”) held its annual general meeting

GOTHENBURG, Sweden, May 19, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that

GOTHENBURG, Sweden, April 30, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes

GÖTEBORG, 15 april 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) hereby invites the shareholders of Isofol Medical AB

GOTHENBURG, Sweden, April 15, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority

GOTHENBURG, Sweden, April 10, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report

GOTHENBURG, Sweden, 31 March 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the exercise period for

GOTHENBURG, Sweden, March 18, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded

GOTHENBURG, Sweden, 13 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) carried out a rights issue of units